1. Freedman RS, Edwards CL, Bowen JM, et al. 1988. Viral oncolysates in patients with advanced ovarian cancer. Gynecol Oncol 29:337–247.
2. Spicer DV, Kelley A, Herman R, Dean G, Stevenson L, Mitchell MS. 1992. Low dose recombinant IL-2 and low-dose cyclophosphamide in metastiatic breast cancer. Cancer Immunol Immunother 34:424–426.
3. Hu S-L, Estin CD, Stevenson US, Hellstrom I, Hellstrom KE. 1988. Recombinant vaccinia virus expressing the human melanoma-associated antigen p97 as a therapeutic antitumor vaccine. In H Ginsberg et al. (eds), Vaccines ′88 New Chemical and Genetic Approaches to Vaccination: Prevention of AIDS and other Viral, Bacterial and Parasitic Diseases. New York: Cold Spring Harbor Laboratory, pp 47–52.
4. Livingston PO. 1989. The basis for ganglioside vaccines in melanoma. In RS Metzgar, MS Mitchell (eds), Human Tumor Antigens and Specific Tumor Therapy. New York: Alan R. Liss, pp 287–296.
5. Harper J, Bumol T, Reisfeld R. 1982. Serological and biochemical analyses of monoclonal antibodies to human melanoma-associated antigens. Hybridoma 1:423–432.